Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Simcere Files to Test Innovative Cancer Drug from US Biopharma

publication date: Mar 11, 2011
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Simcere Pharma has filed an Investigational New Drug (IND) application with the SFDA to start a Phase I trial of a novel monoclonal antibody intended to treat various forms of solid-tumor cancer. The mAb, known as APX003, was discovered by Apexigen of California. Simcere collaborated with Apexigen on the IND-enabling studies and owns China rights to the molecule. To advance its own development program, Apexigen has licensed China rights for three of its molecules to three China companies and collaborated with them on pre-clinical development. More details....

Stock Symbol: (NYSE: SCR)     Share this with colleagues:  



Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
ChinaBio® Events
Shanghai, China
April 14-15, 2015

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors